Ardelyx Inc. has announced the appointment of Sue Hohenleitner as Chief Financial Officer, effective November 4, 2025. Hohenleitner brings over 30 years of experience in corporate finance and previously served as Vice President and CFO of Johnson & Johnson Innovative Medicine North America. She will succeed Justin Renz, who will remain in his role through the completion of Ardelyx's third quarter financial reporting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ardelyx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544245-en) on October 13, 2025, and is solely responsible for the information contained therein.